APO-VORICONAZOLE 50 MG
VORICONAZOLE : 50 MG · DIN 02409674 · APOTEX INC
Health Canada status: DORMANT
What is APO-VORICONAZOLE?
APO-VORICONAZOLE 50 MG contains VORICONAZOLE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02409674, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 02-Jun-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-VORICONAZOLE used for?
Invasive aspergillosis; Candidemia in non-neutropenic patients and specific Candida infections (disseminated skin, abdomen, kidney, bladder wall, and wounds).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02409674 |
|---|---|
| Brand name | APO-VORICONAZOLE |
| Generic / active ingredient | VORICONAZOLE : 50 MG |
| Manufacturer | APOTEX INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J02AC03 VORICONAZOLE |
| AHFS class | 08:14.08 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 02-Jun-2019 |
| Original market date | 2014-04-14 00:00:00 |
How is it administered?
Loading dose: 400 mg BID (Day 1); Maintenance: 200 mg BID. Adjust based on weight (<40 kg) and response. Take 1 hour before or 2 hours after meals. Halve maintenance dose in mild-moderate hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 was listed in TOC but text cut off), though typically 15-30°C for tablets.
How is it supplied?
HDPE bottles of 30 tablets.
Contraindications
Hypersensitivity to voriconazole; coadministration with CYP3A4 substrates (e.g., quinidine, sirolimus, pimozide, lurasidone, ivabradine, naloxegol, tolvaptan, venetoclax) or inducers (e.g., rifampin).
Warnings and precautions
Serious drug interactions; QT interval prolongation; visual disturbances; hepatic toxicity; severe cutaneous adverse reactions (SCARs); teratogenicity; and musculoskeletal (fluorosis/periostitis).
Is VORICONAZOLE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J02AC03 VORICONAZOLE. 11 of 27 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP VORICONAZOLE | 200 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02525798 |
| JAMP VORICONAZOLE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02525771 |
| SANDOZ VORICONAZOLE | 200 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02399253 |
| SANDOZ VORICONAZOLE | 50 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02399245 |
| VFEND | 200 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02256487 |
| VFEND | 200 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02256479 |
| VFEND | 200 MG / 5 ML | POWDER FOR SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 02279991 |
| VFEND | 50 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02256460 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02381966 |
| VORICONAZOLE FOR INJECTION | 200 MG | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02477696 |
Who else supplies VORICONAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VORICONAZOLE appears in 194 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.